Latest Advanz Pharma News & Updates
See the latest news and media coverage for Advanz Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global specialty, hospital, and rare-disease pharmaceutical company
advanzpharma.com- Headquarters
- London, United Kingdom
- Company type
- Public company
- Number of employees
- 700–1,000
Latest news about Advanz Pharma
Company announcements
-
ADVANZ PHARMA announces patent settlement for Eylea biosimilar
Alvotech settles with Regeneron and Bayer, enabling marketing from January 2026 in UK and May 2026 in EEA and Switzerland.
-
Advanz Pharma expands portfolio via acquisition
It acquires additional EMEA rights and global hospital medicine rights, strengthening global footprint and commitment to specialty medicines.
-
Advanz Pharma acquires Progynova, Cyclo-Progynova in EMEA, Ilomedin globally
Progynova treats estrogen deficiency; Cyclo-Progynova regulates menstruation. Ilomedin addresses cardiovascular disorders including rare Thromboangiitis Obliterans. Deals expand specialty brands portfolio following prior Latin America and APAC acquisitions.
-
Advanz Pharma announces EC approval for Gobivaz
The EC granted marketing authorizations for the biosimilar Gobivaz (golimumab) across the EEA for multiple indications and formats.
Media coverage
-
The UK Competition Authority finds a pharmaceutical company guilty of excessive and unfair pricing for Liothyronine Tablets and imposes £101M fine (Advanz) - Concurrences
UK Competition Authority The England & Wales Court of Appeal upholds the Competition Authority’s £99M fine for charging the NHS excessively high prices for a...
-
Advanz Pharma Closes Acquisition of Correvio Pharma | Pharmaceutical Technology
Global pharmaceutical company, Advanz Pharma, has closed its acquisition of specialty pharmaceutical company, Correvio Pharma.
-
Nordic Capital Acquires Advanz Pharma for $846 Million | Pharmaceutical Technology
The acquisition of Advanz Pharma by Nordic Capital has now completed, in a deal worth $846 million.
-
German Court Grants PIs Preventing Marketing of Aflibercept Biosimilars by STADA, Hexal, Celltrion and Advanz Pharma
On 8 January 2026, the Munich Regional Court granted Regeneron and Bayer a preliminary injunction (PI) preventing STADA, Hexal,...
Track Advanz Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Advanz Pharma competitors & trending companies
Browse news for competitors to Advanz Pharma and other trending companies.
FrostPharma
Viatris
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips
Vexlum